8-K current report · filed Nov 9, 2026

Charles River Laboratories (CRL) 8-K Current Report: November 9, 2026

Item 7.01Item EX-99.1CRL overview

Short answer

Charles River Laboratories (CRL) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Acquisition agreement for Frontage Holdings’ bioanalysis and DMPK operations in Exton, Pennsylvania.

Charles River Laboratories 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Acquisition agreement for Frontage Holdings’ bioanalysis and DMPK operations in Exton, Pennsylvania
  • Expands Charles River’s drug-development services footprint through added bioanalysis and DMPK capabilities
  • Transaction terms and expected financial impact require review of Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • Acquisition price approximately $470 million cash, plus up to $75 million performance-based payments
  • Target includes Frontage’s Exton, Pennsylvania bioanalysis and DMPK operations, two sites, approximately 340 employees
  • Acquired businesses represented approximately 40% of Frontage’s 2025 revenue of $256.7 million
  • Closing targeted for first half of 2027, subject to shareholder, regulatory and court approvals
  • Financing through Charles River’s credit facility and available cash, with non-GAAP EPS neutral in 2027 and accretive thereafter

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Charles River Laboratories 8-K filings

Get the next CRL 8-K as it lands

Follow CRL for push alerts, or ask the research agent what this filing means.